Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms

BMC Medical Genetics

Nobuoki Kohno¹  Ulrich Costabel³  Josune Guzman²  Shinichiro Ohshimo¹  Francesco Bonella³  Sonosuke Tanaka¹  Nobuhisa Ishikawa¹  Noboru Hattori¹  Yasushi Horimasu¹ 

[1] Department of Molecular and Internal Medicine, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan;General and Experimental Pathology, Ruhr University Bochum, Universitätsstraße 150, 44801 Bochum, Germany;Department of Pneumology/Allergy, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Tueschener Weg 40, 45239 Essen, Germany

关键词: Surfactant protein-D (SP-D);    Surfactant protein-A (SP-A);    Single nucleotide polymorphism;    Idiopathic interstitial pneumonia;    Biological marker;   

Others  :  1122543
DOI  :  10.1186/1471-2350-15-4

 received in 2013-08-01, accepted in 2014-01-06,  发布年份 2014

【 摘 要 】

Background

Surfactant protein A (SP-A) and SP-D are clinically established in Japan as serum biomarkers for diagnosing interstitial lung diseases (ILDs). Serum SP-D levels are affected by genetic variants. We conducted the present study to examine whether serum SP-A and/or SP-D levels in healthy subjects (HS) and patients with ILDs differ between populations with different genetic backgrounds.

Methods

German subjects (n = 303; 138 patients with idiopathic interstitial pneumonias [IIPs] and 165 HS) and Japanese subjects (n = 369; 94 patients with IIPs and 275 HS) were enrolled. Serum SP-A and SP-D levels were measured using an enzyme-linked immunosorbent assay, and four single-nucleotide polymorphisms (SNPs) in the SFTPD gene were genotyped using genomic DNA extracted from blood samples.

Results

In both the German and Japanese cohorts, serum SP-A and SP-D levels were significantly higher in patients with IIPs than in HS. There were no significant differences in SP-A levels between the German and Japanese cohorts; however, we found that serum SP-D levels were significantly higher in the German cohort, both in patients with IIPs and in HS (p < 0.001 and p = 0.005, respectively). Furthermore, the genotype distributions of the four SNPs in the SFTPD gene (rs721917, rs1998374, rs2243639, and rs3088308) were significantly different between German and Japanese cohorts (p < 0.001, p < 0.001, p = 0.022, and p < 0.001, respectively), and univariate linear regression analyses revealed that the genotypes of rs721917, rs1998374, and rs2243639 significantly correlated with serum SP-D levels (p < 0.001, p < 0.001, and p = 0.011, respectively). Furthermore, multivariate analyses revealed that the genotypes of these three SNPs correlated independently with serum SP-D levels (p < 0.001, p = 0.001, and p = 0.038, respectively), whereas ethnicity did not significantly correlate with serum SP-D levels.

Conclusions

In patients with IIPs and HS, serum SP-D, but not SP-A, levels were significantly higher in the German than in the Japanese cohort, in part, because of the different frequencies of SFTPD gene polymorphisms.

【 授权许可】

   
2014 Horimasu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ohono S, Nakaya T, Bando M, Sugiyama Y: Idiopathic pulmonary fibrosis - results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008, 13:926-928.
• [2]Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150:967-972.
• [3]Hodgson U, Laitinen T, Tukiainen P: Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002, 57:338-342.
• [4]Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Ch L, Bouros D, Hellenic Interstitial Lung Diseases Group: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009, 103:1122-1129.
• [5]American Thoracic Society, European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002, 165:277-304.
• [6]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al.: ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
• [7]Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, Honda Y, Abe S, Akino T: Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993, 147:723-729.
• [8]Selman M, Pardo A: Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006, 3:364-372.
• [9]Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ: Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446.
• [10]Prasse A, Müller-Quernheim J: Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009, 14:788-795.
• [11]Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG: Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res 2010, 11:89. BioMed Central Full Text
• [12]van den Blink B, Wijsenbeek MS, Hoogsteden HC: Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010, 23:515-520.
• [13]Nukiwa T: The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. In European Respiratory Monograph. Volume 46. Edited by Du Bois RM, Richeldi L. UK: ERS Journals Ltd; 2009:47-66.
• [14]Ishikawa N, Hattori N, Yokoyama A, Kohno N: Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012, 50:3-13.
• [15]Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012, 18:441-446.
• [16]Kashiwabara K: Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. Chest 2006, 129:402-406.
• [17]Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S: Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 2006, 11:S51-S54.
• [18]Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K: The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med 2010, 104:1712-1721.
• [19]Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, Yokoyama A, Kohno N, Bonella F, Guzman J, Ohshimo S, Costabel U: Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir Med 2012, 106:1756-1764.
• [20]Janssen R, Kruit A, Grutters JC, Ruven HJ, Gerritsen WB, van den Bosch JM: The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol 2006, 34:496-499.
• [21]Heidinger K, König IR, Bohnert A, Kleinsteiber A, Hilgendorff A, Gortner L, Ziegler A, Chakraborty T, Bein G: Polymorphisms in the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics 2005, 57:1-7.
• [22]Sørensen GL, Hjelmborg JB, Kyvik KO, Fenger M, Høj A, Bendixen C, Sørensen TI, Holmskov U: Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1010-L1017.
• [23]Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P, Gulsvik A, Lomas DA, Litonjua AA, Shapiro SD, Tal-Singer R, Silverman EK: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011, 44:316-322.
• [24]International HapMap Project [http://hapmap.ncbi.nlm.nih.gov/index.html.en webcite]
• [25]Kanehara M, Yokoyama A, Tomoda Y, Shiota N, Iwamoto H, Ishikawa N, Taooka Y, Haruta Y, Hattori N, Kohno N: Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008, 21:874-878.
• [26]Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, Hattori N, Hara H, Kohno N: Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009, 179:35-40.
• [27]Yamane T, Hattori N, Kitahara Y, Haruta Y, Sasaki H, Yokoyama A, Kohno N: Productive cough is an independent risk factor for the development of COPD in former smokers. Respirology 2010, 15:313-318.
• [28]Ishikawa N, Hattori N, Tanaka S, Horimasu Y, Haruta Y, Yokoyama A, Kohno N, Kinnula VL: Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysis. Respiration 2011, 82:10-18.
• [29]Standardization of Spirometry, 1994 Update. American Thoracic Society Am J Respir Crit Care Med 1995, 152:1107-1136.
• [30]Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N: Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002, 165:378-381.
• [31]Hiyama E, Yokohama T, Hiyama K, Yamakido M, Santo T, Kodama T, Ichikawa T, Matsuura Y: Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int J Oncol 1995, 6:13-16.
• [32]Shiels MS, Chaturvedi AK, Katki HA, Gochuico BR, Caporaso NE, Engels EA: Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:2262-2272.
• [33]Holmskov U, Thiel S, Jensenius JC: Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003, 21:547-578.
• [34]Crouch E, Persson A, Chang D: Accumulation of surfactant protein D in human pulmonary alveolar proteinosis. Am J Pathol 1993, 142:241-248.
• [35]Crouch E, Persson A, Chang D, Heuser J: Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem 1994, 269:17311-17319.
• [36]Leth-Larsen R, Garred P, Jensenius H, Meschi J, Hartshorn K, Madsen J, Tornoe I, Madsen HO, Sørensen G, Crouch E, Holmskov U: A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol 2005, 174:1532-1538.
• [37]Wright JR: Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005, 5:58-68.
• [38]Selman M, Lin HM, Montaño M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, Lang CM, Pardo A, Phelps DS, Floros J: Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003, 113:542-550.
• [39]García-Laorden MI, Rodríguez de Castro F, Solé-Violán J, Rajas O, Blanquer J, Borderías L, Aspa J, Briones ML, Saavedra P, Marcos-Ramos JA, González-Quevedo N, Sologuren I, Herrera-Ramos E, Ferrer JM, Rello J, Rodríguez-Gallego C: Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Crit Care 2011, 15:R57. BioMed Central Full Text
• [40]Ishii T, Hagiwara K, Kamio K, Ikeda S, Arai T, Mieno MN, Kumasaka T, Muramatsu M, Sawabe M, Gemma A, Kida K: Involvement of surfactant protein D in emphysema revealed by genetic association study. Eur J Hum Genet 2012, 20:230-235.
• [41]Ishii T, Hagiwara K, Ikeda S, Arai T, Mieno MN, Kumasaka T, Muramatsu M, Sawabe M, Gemma A, Kida K: Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population. COPD 2012, 9:409-416.